Targeting DNA methylation
JPJ Issa, HM Kantarjian - Clinical Cancer Research, 2009 - AACR
Two nucleoside inhibitors of DNA methylation, azacitidine and decitabine, are now standard
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …
[PDF][PDF] Targeting DNA Methylation
JPJ Issa, HM Kantarjian - Clin Cancer Res, 2009 - researchgate.net
Two nucleoside inhibitors of DNA methylation, azacitidine and decitabine, are now standard
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …
[PDF][PDF] Targeting DNA Methylation
JPJ Issa, HM Kantarjian - Clin Cancer Res, 2009 - Citeseer
Two nucleoside inhibitors of DNA methylation, azacitidine and decitabine, are now standard
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …
Targeting DNA methylation
JPJ Issa, HM Kantarjian - Clinical Cancer Research, 2009 - mdanderson.elsevierpure.com
Two nucleoside inhibitors of DNA methylation, azacitidine and decitabine, are now standard
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …
Targeting DNA methylation.
JP Issa, HM Kantarjian - … Cancer Research: an Official Journal of …, 2009 - europepmc.org
Two nucleoside inhibitors of DNA methylation, azacitidine and decitabine, are now standard
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …
Targeting DNA methylation
JPJ Issa, HM Kantarjian - Clinical cancer research: an …, 2009 - pubmed.ncbi.nlm.nih.gov
Two nucleoside inhibitors of DNA methylation, azacitidine and decitabine, are now standard
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …
[HTML][HTML] Targeting DNA Methylation
JPJ Issa, HM Kantarjian - … cancer research: an official journal of the …, 2009 - ncbi.nlm.nih.gov
Two nucleoside inhibitors of DNA methylation, azacitidine and decitabine, are now standard
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …
[PDF][PDF] Targeting DNA Methylation
JPJ Issa, HM Kantarjian - Clin Cancer Res, 2009 - cyberleninka.org
Two nucleoside inhibitors of DNA methylation, azacitidine and decitabine, are now standard
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …
Targeting DNA Methylation
JPJ Issa, HM Kantarjian - Clinical Cancer Research, 2009 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Two nucleoside inhibitors of DNA methylation,
azacitidine and decitabine, are now standard of care for the treatment of the myelodysplastic …
azacitidine and decitabine, are now standard of care for the treatment of the myelodysplastic …
Targeting DNA methylation.
JP Issa, HM Kantarjian - … Cancer Research: an Official Journal of …, 2009 - europepmc.org
Two nucleoside inhibitors of DNA methylation, azacitidine and decitabine, are now standard
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …